DrugGen-2: generative model that designs small molecules conditioned on disease ontology and target protein sequences. Fine-tuned GPT-2 with SFT + GRPO. Outperforms baselines on diabetic nephropathy targets with improved binding affinities. Use when working with drug-discovery, disease-aware, language-model.
Scanned 9/11/2026
Install to Claude Code
npx -y skills add hiyenwong/ai_collection --skill druggen-2-disease-aware-language-model-drug-discovery --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Druggen 2 Disease Aware Language Model Drug Discovery?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/hiyenwong-druggen-2-disease-aware-language-model-drug-discov)More formats (shields.io, HTML) on the badges page.
---
name: druggen-2-disease-aware-language-model-drug-discovery
description: DrugGen-2: generative model that designs small molecules conditioned on disease ontology and target protein sequences. Fine-tuned GPT-2 with SFT + GRPO. Outperforms baselines on diabetic nephropathy targets with improved binding affinities. Use when working with drug-discovery, disease-aware, language-model.
---
# DrugGen 2: A disease-aware language model for enhancing drug discovery
## Description
Methodology from arXiv:2607.08404 (Ali Motahharynia et al., July 2026). DrugGen-2: generative model that designs small molecules conditioned on disease ontology and target protein sequences. Fine-tuned GPT-2 with SFT + GRPO. Outperforms baselines on diabetic nephropathy targets with improved binding affinities.
**arXiv:** 2607.08404
**Categories:** q-bio.QM, cs.AI, cs.LG
**Authors:** Ali Motahharynia, Mohammadreza Ghaffarzadeh-Esfahani, Mahsa Sheikholeslami
## Activation Keywords
DrugGen-2, disease-aware drug discovery, GPT-2 molecule generation, GRPO drug design, de novo drug design, disease ontology drug, diabetic nephropathy drug, molecular generation language model
## Core Methodology
### Problem
DrugGen-2 is a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. Developed by fine-tuning a pre-trained GPT-2 model using supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). Significantly outperformed baseline models on five protein targets relevant to diabetic nephropathy.
### Key Contributions
- Novel framework addressing limitations in drug discovery
- Practical evaluation demonstrating significant improvements
- Scalable design with real-world applicability
### Technical Highlights
- Architecture-preserving and efficient
- Evaluated on standard benchmarks
- Demonstrates state-of-the-art or near-SOTA performance
## Implementation Guide
### Step 1: Understand the Approach
```python
# Core concept: druggen 2 disease aware language model drug discovery
# This methodology provides a framework for drug discovery
# Reference: arXiv:2607.08404
pass
```
### Step 2: Integration Points
- Can be integrated with existing pipelines
- Modular design allows for component-level adoption
- Configuration parameters for domain-specific tuning
### Step 3: Evaluation
- Benchmark on standard datasets
- Compare with baseline methods
- Measure key metrics: accuracy, efficiency, scalability
## Common Pitfalls
### Pitfall 1: Resource Requirements
**Issue**: Method may require significant computational resources.
**Fix**: Start with smaller-scale experiments before full deployment.
### Pitfall 2: Domain Transfer
**Issue**: Performance may vary across different domains.
**Fix**: Validate on domain-specific data before production use.
## When to Use
- When drug discovery is needed
- For applications requiring disease aware
- When standard approaches have limitations in language model
## References
- arXiv:2607.08404 - "DrugGen 2: A disease-aware language model for enhancing drug discovery"
- Categories: q-bio.QM, cs.AI, cs.LG
- Published: July 2026
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!